{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:34:35Z","timestamp":1761896075430},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jdiacomp.2015.05.022","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T21:27:14Z","timestamp":1433626034000},"page":"1266-1271","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Priscilla","family":"Hollander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Vlajnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Kilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0005","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2015.05.022_bb0010","first-page":"S5","article-title":"Standards of medical care in diabetes\u20132015","volume":"38","author":"American Diabetes Association (ADA)","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0015","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/hep.25509","article-title":"Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus","volume":"55","author":"Chang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/dmrr.1305","article-title":"Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: A patient-level pooled analysis","volume":"28","author":"Chaudhuri","year":"2012","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17925\/EE.2014.10.01.23","article-title":"A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes","volume":"10","author":"DeVries","year":"2014","journal-title":"European Endocrinology"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0030","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/jc.2011-2202","article-title":"Update on insulin therapy for type 2 diabetes","volume":"97","author":"Donner","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0040","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1463-1326.2011.01412.x","article-title":"An analysis of early insulin glargine added to metformin with or without sulfonylurea: Impact on glycaemic control and hypoglycaemia","volume":"13","author":"Fonseca","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/14746514020020011801","article-title":"Plasma lipids and antidiabetic agents: A brief overview","volume":"2","author":"Keidan","year":"2002","journal-title":"British Journal of Diabetes and Vascular Disease"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0060","series-title":"US Endocrine Disease (Touch Briefings Endocrinology)","article-title":"Aggressive management of blood glucose","author":"Kilo","year":"2007"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0065","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1592\/phco.24.6.606.34752","article-title":"Sulfonylurea treatment of type 2 diabetes: Focus on glimepiride","volume":"24","author":"Korytkowski","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0070","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc09-0653","article-title":"Insulin-based versus triple oral therapy for newly-diagnosed type 2 diabetes: Which is better?","volume":"32","author":"Lingvay","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0075","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4158\/EP09281.OR","article-title":"Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus","volume":"16","author":"Meneghini","year":"2010","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0085","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/dc10-2412","article-title":"Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting","volume":"34","author":"Piccinni","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0090","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2337\/dc07-0002","article-title":"Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study","volume":"30","author":"Porcellati","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0095","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0100","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.2337\/diacare.26.8.2238","article-title":"Insulin 70\/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: Efficacy, safety, and cost analysis","volume":"26","author":"Schwartz","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0110","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2015.05.022_bb0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715002251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715002251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T02:20:19Z","timestamp":1537582819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872715002251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1056872715002251"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.05.022","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}